Smirnov V S, Garshinina A V, Guseva V M, Kalinina N A, Shtro A A, Beliaevskaia S V, Anikin V B, Zarubaev V V
Vopr Virusol. 2013 Sep-Oct;58(5):19-26.
Influenza virus is a leading causing factor of infectious respiratory human pathology. The ability to implement the antigenic drift and development of drug resistance makes it important to develop novel anti-influenza drugs of wide spectrum of activity. In this work, we present the results of the study of the activity of a combination of glycyrrhizic acid with dipeptide alpha-glutamyl-tryptophan against oseltamivir-reistant strain of the virus Al Vladivostok/2/09 (H1 N1) on the model of lethal influenza infection in white mice. Application of Orvilax was shown to decrease the specific mortality of animals (index of protection 39-67% depending on the dose of the virus and drugs combination), to increase the mean day of death to 3.7-5.0 days and decrease the infectious titer of the virus in lung tissue to 1.3 Ig EID50/20 mg. The corresponding figures for the reference compound Tamiflu were 8-11%, 0.5-1.5 days, and 0.6 Ig EID50/20 mg. The use of Orvilax also led to reliable increase of the titers of interferon in the blood from 30.4 to 56.5 ME/mL. The results obtained allow the drug to be considered as a promising anti-influenza remedy that is active against the drug-resistant virus strains.
流感病毒是人类呼吸道感染性疾病的主要致病因素。其具备抗原漂移能力以及产生耐药性，这使得研发具有广泛活性的新型抗流感药物变得至关重要。在本研究中，我们展示了甘草酸与二肽α-谷氨酰-色氨酸组合对病毒海参崴/2/09（H1N1）奥司他韦耐药株在小白鼠致死性流感感染模型上的活性研究结果。结果表明，使用Orvilax可降低动物的特异性死亡率（保护指数为39%-67%，取决于病毒和药物组合的剂量），将平均死亡天数延长至3.7-5.0天，并将肺组织中病毒的感染滴度降低至1.3 Ig EID50/20 mg。参比化合物达菲的相应数据分别为8%-11%、0.5-1.5天和0.6 Ig EID50/20 mg。使用Orvilax还可使血液中干扰素滴度从30.4可靠地提高至56.5 ME/mL。所得结果表明，该药物可被视为一种有前景的抗流感药物，对耐药病毒株具有活性。
